Innovent Reports NMPA's Acceptance of sNDA for Sintilimab as 1L Treatment for Esophageal Squamous Cell Carcinoma
Shots:
- The sNDA is based on the P-III ORIENT-15 clinical trial evaluates sintilimab + CT vs PBO + CT in a ratio (1:1) in 659 patients unresectable LA- recurrent or metastatic ESCC
- In an interim analysis- the therapy demonstrated an improvement in the 1EPs of OS & PFS. The results were presented at ESMO 2021
- Sintilimab is an innovative PD-1 inhibitor- jointly developed by Eli Lilly and Innovent. Additionally- Innovent has two regulatory submissions under review in China for sintilimab as 1L or 2L treatment of ESCC & NSCLC & is currently conducting 20+ clinical studies of sintilimab for multiple cancer
Click here | Ref: PR Newswire | Image: Innovent
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com